Dermatology & Plastic Surgery Institute Outcomes
Surgical Quality Improvement
Breast Reconstruction
Breast Reconstruction ACS NSQIP Outcomes
January 1, 2022– December 31, 2022
The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) objectively measures and reports risk-adjusted surgical outcomes based on a defined sampling and abstraction methodology. These outcomes data reflect Cleveland Clinic’s overall breast reconstruction surgery ACS NSQIP performance benchmarked against 342 participating sites.
| Breast Reconstruction (342 Sites) | N | Observed | Expected |
|---|---|---|---|
| 30 Day Morbidity | 351 | 3.70% | 5.94% |
| Pneumonia | 351 | 0.00% | 0.07% |
| Deep Vein Thrombosis (DVT) / Pulmonary Embolus | 351 | 0.85% | 0.44% |
| Renal Failure | 351 | 0.00% | 0.07% |
| Surgical Site Infection (SSI) | 349 | 3.15% | 4.76% |
| Sepsis | 351 | 0.28% | 0.47% |
| Unplanned Reoperation | 351 | 5.70% | 5.10% |
| Unplanned Readmissionᵃ | 351 | 5.41% | 2.96% |
American College of Surgeons National Surgical Quality Improvement Program, 2023.
ACS NSQIP® Semiannual Report July 3, 2023, Chicago: American College of Surgeons.
ᵃIdentified as a statistical outlier (higher than expected) by the ACS NSQIP hierarchical model.
